The burden of pneumococcal disease

The role of conjugate vaccines

Gregory A. Poland

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The pneumococcus remains a major cause of morbidity and mortality in both underdeveloped and developed countries. Although there are licensed, safe vaccines against invasive pneumococcal disease currently available in the US and Europe, several major dilemmas are apparent. First, the efficacy of these vaccines in high risk immunocompetent adults is only moderate, with limited or no immunogenicity in very high risk, immunocompromised adults. Secondly, efficacy of the vaccine against pneumococcal pneumonia in adults is controversial. Thirdly, the current vaccines are not efficacious in children < 2 years of age, which is problematic given the high rate of invasive disease among this age group. The solution to these dilemmas may lie in the development of protein conjugate-polysaccharide vaccines. This paper briefly reviews the role of conjugate pneumococcal vaccines.

Original languageEnglish (US)
Pages (from-to)1674-1679
Number of pages6
JournalVaccine
Volume17
Issue number13-14
DOIs
StatePublished - Jan 1999

Fingerprint

Conjugate Vaccines
burden of disease
Vaccines
vaccines
Pneumococcal Pneumonia
Pneumococcal Vaccines
Streptococcus pneumoniae
Developed Countries
Polysaccharides
Age Groups
Morbidity
developed countries
pneumonia
morbidity
Mortality
developing countries
polysaccharides
immune response
Proteins
proteins

Keywords

  • Pneumococcal vaccine
  • Protein conjugate

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

The burden of pneumococcal disease : The role of conjugate vaccines. / Poland, Gregory A.

In: Vaccine, Vol. 17, No. 13-14, 01.1999, p. 1674-1679.

Research output: Contribution to journalArticle

Poland, Gregory A. / The burden of pneumococcal disease : The role of conjugate vaccines. In: Vaccine. 1999 ; Vol. 17, No. 13-14. pp. 1674-1679.
@article{77925d4bf4f14ab29c80fb8355b12b78,
title = "The burden of pneumococcal disease: The role of conjugate vaccines",
abstract = "The pneumococcus remains a major cause of morbidity and mortality in both underdeveloped and developed countries. Although there are licensed, safe vaccines against invasive pneumococcal disease currently available in the US and Europe, several major dilemmas are apparent. First, the efficacy of these vaccines in high risk immunocompetent adults is only moderate, with limited or no immunogenicity in very high risk, immunocompromised adults. Secondly, efficacy of the vaccine against pneumococcal pneumonia in adults is controversial. Thirdly, the current vaccines are not efficacious in children < 2 years of age, which is problematic given the high rate of invasive disease among this age group. The solution to these dilemmas may lie in the development of protein conjugate-polysaccharide vaccines. This paper briefly reviews the role of conjugate pneumococcal vaccines.",
keywords = "Pneumococcal vaccine, Protein conjugate",
author = "Poland, {Gregory A.}",
year = "1999",
month = "1",
doi = "10.1016/S0264-410X(98)00435-6",
language = "English (US)",
volume = "17",
pages = "1674--1679",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "13-14",

}

TY - JOUR

T1 - The burden of pneumococcal disease

T2 - The role of conjugate vaccines

AU - Poland, Gregory A.

PY - 1999/1

Y1 - 1999/1

N2 - The pneumococcus remains a major cause of morbidity and mortality in both underdeveloped and developed countries. Although there are licensed, safe vaccines against invasive pneumococcal disease currently available in the US and Europe, several major dilemmas are apparent. First, the efficacy of these vaccines in high risk immunocompetent adults is only moderate, with limited or no immunogenicity in very high risk, immunocompromised adults. Secondly, efficacy of the vaccine against pneumococcal pneumonia in adults is controversial. Thirdly, the current vaccines are not efficacious in children < 2 years of age, which is problematic given the high rate of invasive disease among this age group. The solution to these dilemmas may lie in the development of protein conjugate-polysaccharide vaccines. This paper briefly reviews the role of conjugate pneumococcal vaccines.

AB - The pneumococcus remains a major cause of morbidity and mortality in both underdeveloped and developed countries. Although there are licensed, safe vaccines against invasive pneumococcal disease currently available in the US and Europe, several major dilemmas are apparent. First, the efficacy of these vaccines in high risk immunocompetent adults is only moderate, with limited or no immunogenicity in very high risk, immunocompromised adults. Secondly, efficacy of the vaccine against pneumococcal pneumonia in adults is controversial. Thirdly, the current vaccines are not efficacious in children < 2 years of age, which is problematic given the high rate of invasive disease among this age group. The solution to these dilemmas may lie in the development of protein conjugate-polysaccharide vaccines. This paper briefly reviews the role of conjugate pneumococcal vaccines.

KW - Pneumococcal vaccine

KW - Protein conjugate

UR - http://www.scopus.com/inward/record.url?scp=0344267653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344267653&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(98)00435-6

DO - 10.1016/S0264-410X(98)00435-6

M3 - Article

VL - 17

SP - 1674

EP - 1679

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13-14

ER -